Binlong Chen, Ph.D.


      Associate professor (research-track)

      Department of Pharmaceutics

      School of Pharmaceutical Sciences, Peking University

      38 Xueyuan Road, Haidian District, Beijing 100191

Mobile phone: +86-10-82805127, E-mail: binlong.chen@pku.edu.cn


Education and Professional Career

    • 2023.8-present      Associate Professor (research-track), School of Pharmaceutical Sciences, Peking University
    • 2023.11-2024.11    Postdoctoral Fellow, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

                                      (Advisor: Prof. Daniel G. Anderson and Prof. Robert S. Langer)

    • 2022.7-2023.7       Assistant Professor (research-track), School of Pharmaceutical Sciences, Peking University
    • 2018.7-2022.6       Postdoctoral Fellow, School of Pharmaceutical Sciences, Peking University (Advisor: Prof. Yiguang Wang)
    • 2015.9-2018.6        Ph.D. in Pharmaceutics, Peking University, Beijing, China (Advisor: Prof. Qiang Zhang and Prof. Yiguang Wang)
    • 2013.9-2015.7       M.Sc. in Pharmaceutics, Peking University, Beijing, China (Advisor: Prof.  Qiang Zhang)
    • 2009.9-2013.7        B.Sc. in Pharmacy, Peking University, Beijing, China

    Award and Honors

    • 2024     Young Talent Promotion Project of Beijing Association for Science and Technology
    • 2022     Cutting-edge academic achievements in the capital
    • 2021     Outstanding Postdoctoral Prize of Peking University
    • 2018     National Postdoctoral Program for Innovative Talents of China Postdoctoral Foundation 

    Selected Publications

    1.    Chen BL, Yan Y, Yang Y, Cao G, Wang X, Wang Y, Wan F, Yin Q, Wang Z, Li Y, Wang L, Xu B, You F*, Zhang Q*, Wang YG*. A pyroptosis nanotuner for cancer therapy. Nature Nanotechnology. 202217, 788-798.

    2.   Liu J#, Yan Y#, Zhang Y, Pan X, Xia H, Wan F, Huang X, Zhang Q, Chen BL*, Wang YG*. Lysosome-mitochondria cascade targeting nanoparticle drives robust pyroptosis for cancer immunotherapy. J. Am. Chem. Soc. 2024, 146, 34568-34582. 

    3.    Wan F#, Wang L#, Zhao R,  Xia H, Liu J, Yan Y, Deng F, Zhang Q, Wang YG*, Chen BL*. A general strategy towards early endosome-stressed nanophotosensitizers for pyroptotic cancer therapy. Nano Today. 2024, 57, 102350. 

    4.   Cui Y,  Xia H, Liu Q, Ma B, Pan M, Shang C, Zhang Q, Wang YG, Chen BL*, Guo HY*. A Tumor-activatable liposomal nanoprobe for selective visualization of metastatic lymph nodes. Advanced Healthcare Materials. 2024, 2401935. 

    5.   Qin M, Xia H, Xu W, Chen BL*, Wang YG*. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy. Advanced Drug Delivery Reviews. 2023, 203, 115137. 

    6.      Yan Y, Chen BL, Yin Q, Wang Z, Yang Y, Wan F, Wang Y, Tang M, Xia H, Chen M, Liu J, Wang S, Zhang Q, WangYG*. Dissecting extracellular and intracellular distribution of nanoparticles and their contribution to therapeutic response by monochromatic ratiometric imaging. Nature Communications2022, 13, 2004.

    7.   Chen BL, Yang Y, Wang Y, Yan Y, Wang Z, Yin Q, Zhang Q, Wang YG*. Precise Monitoring of Singlet Oxygen in Specific Endocytic Organelles by Super-pH-Resolved Nanosensors. ACS Applied Materials &Interfaces. 2021, 13, 18533-18544.

    8.   Chen BL, Dai W*, Mei D, Liu T, Li S, He B, He B, Yuan L, Zhang H, Wang X, Zhang Q*. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. Journal of Controlled Release2016, 241, 68-80.

    9.    Chen BL, Wang Z, Sun J, Song Q, Li S, He B, Zhang H, Wang X, Dai W*, Zhang Q*. A tenascin C targeted nanoliposome with navitoclax for specifically eradicating of cancer-associated fibroblasts. Nanomedicine:Nanotechnology, Biology, and Medicine. 2016, 12, 131-141.

    10.  Chen BL, Dai W*, He B, Zhang H, Wang X, Wang YG, Zhang Q*. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics2017, 7, 538-558. (Highly cited paper)